Mikhail Lichinitser - Researcher Profile

Publications

3 shown

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont , Christian U. Blank , Mario Mandalà +26 more

As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free surviv...

2018 New England Journal of Medicine 1753 citations

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Yoon‐Koo Kang , Won Ki Kang , D.B. Shin +12 more

2009 Annals of Oncology 766 citations

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart , Marion Procter , Brian Leyland‐Jones +29 more

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov...

2005 New England Journal of Medicine 5034 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 7,553
Institution: Russian Cancer Research Center NN Blokhin

External Links

Google Scholar

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.